Revolution Medicines, Inc. Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Amount
Revolution Medicines, Inc. (RVMD) reported Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Amount of -$50.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxContingenciesForeign · last filed 2025-02-26
- Revolution Medicines, Inc. effective income tax rate reconciliation, tax contingency, foreign, amount for fiscal 2024 was -$50.00K, a 106.31% decline from fiscal 2023.
- Revolution Medicines, Inc. effective income tax rate reconciliation, tax contingency, foreign, amount for fiscal 2023 was $792.00K.
- Revolution Medicines, Inc. effective income tax rate reconciliation, tax contingency, foreign, amount for fiscal 2022 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Tax Contingency, Foreign, Amount 12 month |
|---|---|
| 2024-12-31 | -$50.00K 10-K · filed 2025-02-26 |
| 2023-12-31 | $792.00K 10-K · filed 2025-02-26 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |